MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

NCT04074564 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma

Interventions

COMBINATION_PRODUCT: MASCT-I, Camrelizumab,Apatinib

Sponsor

HRYZ Biotech Co.